Skip to main content
An official website of the United States government

Funded Grants

PI Name Sort descending PI Organization Title Grant Number Initiative Program Official
Sigel, Keith Magnus

Icahn School Of Medicine At Mount Sinai
United States

The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors 5R01CA256660-04 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Simeone, Diane M

University Of California, San Diego
United States

Biomarker Validation in Pancreatic Cystic Neoplasms 7U01CA282272-02 PAR-21-334 (U01 Clinical Trial Optional) Matthew Young, Ph.D.
Siminski, Suzanne M.

Frontier Sci & Technology Rsch Fdn, Inc
United States

CASCADE Coordinating Center 5U24CA275417-04 Maria Silvina Frech, Ph.D., M.S.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States 5U01CA230694-05
Singal, Amit

Ut Southwestern Medical Center
United States

Clinical Validation Center for Hepatocellular Carcinoma 5U01CA271887-04 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis 5R01CA222900-06
Siskind, Leah J

University Of Louisville
United States

Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease 1R01CA305985-01 Marjorie Perloff, M.D.
Skates, Steven J

Massachusetts General Hospital
United States

Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls 5U01CA260758-05 PAR-18-913 (U01 Clinical Trial Not Allowed) Claire Zhu, Ph.D.
Skubitz, Amy Patrice

University Of Minnesota
United States

A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection 5R01CA262153-05 PA-20-185 (Parent R01 Clinical Trial Not Allowed) Christos Patriotis, Ph.D., M.Sc.
Smith, Ellen Mary Lavoie

University Of Alabama At Birmingham
United States

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study 5R01CA235726-07 Brennan Streck, Ph.D., RN, M.P.H.